Skip to Main Content

Advertisement

Skip Nav Destination

OnlineFirst

Review Article June 24 2022
Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy
Clin Cancer Res clincanres.1129.2022-1-19 13:21:38.193.
Research Article June 23 2022
Classification of BRCA2 variants of uncertain significance (VUS) using an ACMG/AMP model incorporating a homology directed repair (HDR) functional assay
Clin Cancer Res clincanres.0203.2022.
Brief Report June 23 2022
Tumor immune microenvironment changes by multiplex immunofluorescence staining in a pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a hereditary BRCA mutation
Clin Cancer Res clincanres.1278.2021.
Article Commentary June 23 2022
Shining a FLASHlight on ultrahigh dose rate radiation and possible late toxicity
Clin Cancer Res clincanres.1255.2022-5-10 22:17:03.080.
Review Article June 23 2022
FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma
Clin Cancer Res clincanres.0618.2022-2-24 13:00:26.277.
Research Article June 23 2022
Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study
Clin Cancer Res (2022)
Research Article June 23 2022
Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma
Clin Cancer Res (2022)
Research Article June 23 2022
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
Clin Cancer Res (2022)
Research Article June 23 2022
Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition
Clin Cancer Res (2022)
Research Article June 23 2022
SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of Phase I Study
Clin Cancer Res (2022)
Research Article June 23 2022
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2 ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
Clin Cancer Res (2022)
Research Article June 23 2022
FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer
Clin Cancer Res (2022)
Research Article June 23 2022
Osimertinib plus Selumetinib in EGFR-Mutated Non–Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B)
Clin Cancer Res (2022)
Research Article June 23 2022
OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma
Clin Cancer Res (2022)
Research Article June 23 2022
Phenotype, Function, and Clinical Significance of CD26+ and CD161+Tregs in Splenic Marginal Zone Lymphoma
Clin Cancer Res (2022)
Research Article June 21 2022
Membrane-anchored and tumor-targeted IL-12 (attIL12)-PBMC therapy for osteosarcoma
Clin Cancer Res clincanres.0721.2022-3-6 00:45:30.140.
Brief Report June 21 2022
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker subanalysis
Clin Cancer Res clincanres.0588.2022-2-21 11:01:45.430.
Research Article June 21 2022
Novel Radiomic Measurements of Tumor-Associated Vasculature Morphology on Clinical Imaging as a Biomarker of Treatment Response in Multiple Cancers
Clin Cancer Res clincanres.CCR-21-4148-A.2021.
Research Article June 21 2022
Anti-cancer activity of the combination of cabozantinib and temozolomide in uterine sarcoma
Clin Cancer Res clincanres.0985.2022-3-26 05:38:56.960.
Review Article June 21 2022
FDA Approval Summary: Belzutifan for von Hippel-Lindau disease associated tumors
Clin Cancer Res clincanres.1054.2022-4-4 11:16:38.037.
Research Article June 21 2022
Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL
Clin Cancer Res (2022)
Research Article June 21 2022
CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Clin Cancer Res (2022)
Research Article June 21 2022
VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results
Clin Cancer Res (2022)
Research Article June 21 2022
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
Clin Cancer Res (2022)
Research Article June 21 2022
Phase II Clinical Trial of Eribulin–Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma
Clin Cancer Res (2022)
Research Article June 21 2022
EWS::FLI1 and HOXD13 Control Tumor Cell Plasticity in Ewing Sarcoma
Clin Cancer Res (2022)
Research Article June 21 2022
Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer
Clin Cancer Res (2022)
Research Article June 21 2022
Mechanistic Modeling of Central Nervous System Pharmacokinetics and Target Engagement of HER2 Tyrosine Kinase Inhibitors to Inform Treatment of Breast Cancer Brain Metastases
Clin Cancer Res (2022)
Research Article June 21 2022
Circulating Tumor DNA–Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax
Clin Cancer Res (2022)
Research Article June 21 2022
PD-L1 Crosslinking as a New Strategy of 4-1BB Agonism Immunotherapy
Clin Cancer Res (2022)
Research Article June 21 2022
Omission of Upfront Craniospinal Irradiation in Patients with Low-Risk WNT-Pathway Medulloblastoma Is Associated with Unacceptably High Risk of Neuraxial Failure
Clin Cancer Res (2022)
Article Commentary June 21 2022
Targeting Ferroptosis Vulnerability in Synovial Sarcoma: Is it all about ME1?
Clin Cancer Res clincanres.1257.2022-5-1 22:00:31.200.
Article Commentary June 21 2022
Combination therapies for advanced hepatocellular carcinoma: biomarkers and unmet needs
Clin Cancer Res clincanres.1213.2022-5-9 09:17:35.930.
Research Article June 17 2022
Circulating tumor DNA (ctDNA) kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403)
Clin Cancer Res clincanres.CCR-22-0741-A.2022-3-8 14:09:41.447.
Research Article June 17 2022
Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study
Clin Cancer Res clincanres.CCR-22-0446-A.2022-2-9 22:21:43.437.
Research Article June 15 2022
Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Syndrome in B-Cell ALL Patients Receiving CART19
Clin Cancer Res clincanres.CCR-22-0822-E.2022-3-15 10:15:45.960.
Research Article June 15 2022
Novel DNA Methylation Biomarker Panel for Detection of Esophageal Adenocarcinoma and High-grade Dysplasia
Clin Cancer Res clincanres.0445.2022-2-11 17:32:55.870.
Research Article June 14 2022
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
Clin Cancer Res clincanres.4020.2021.
Research Article June 14 2022
Safety and tolerability of MEDI0562, an OX40 agonist monoclonal antibody, in combination with durvalumab or tremelimumab in adult patients with advanced solid tumors
Clin Cancer Res clincanres.3016.2021-9-6 10:18:17.230.
Research Article June 13 2022
Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratification
Clin Cancer Res clincanres.0368.2022-2-2 06:00:14.580.
Research Article June 13 2022
Assessment of Androgen Receptor splice variant-7 as a biomarker of clinical response in castration-sensitive prostate cancer
Clin Cancer Res clincanres.0851.2022-3-16 14:26:47.417.
Research Article June 13 2022
FOXM1 variant contributes to gefitinib resistance via activating wnt/β-catenin signal pathway in non-small cell lung cancer patients
Clin Cancer Res clincanres.0791.2022-3-11 20:24:57.550.
Research Article June 10 2022
Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a fourth- or later-line therapy
Clin Cancer Res clincanres.0196.2022-1-20 08:35:31.930.
Review Article June 10 2022
Facts and hopes in the relationship of EBV with cancer immunity and immunotherapy
Clin Cancer Res clincanres.3408.2022-2-28 16:51:58.077.
Research Article June 10 2022
A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma
Clin Cancer Res (2022)
Research Article June 10 2022
Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma
Clin Cancer Res (2022)
Research Article June 10 2022
Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction
Clin Cancer Res (2022)
Research Article June 9 2022
Updated efficacy outcomes of anti-PD-1 antibodies plus multikinase inhibitors for advanced gastric cancer patients with or without liver metastases in clinical trials
Clin Cancer Res clincanres.0630.2022-2-27 11:45:33.693.
Research Article June 9 2022
Deuterium metabolic imaging reports on TERT expression and early response to therapy in cancer
Clin Cancer Res clincanres.CCR-21-4418-A.2021.
Research Article June 8 2022
Phase II study of TQB2450, a novel PD-L1 antibody, in combination with anlotinib in patients with locally advanced or metastatic soft tissue sarcoma
Clin Cancer Res clincanres.0871.2022-3-18 10:13:03.583.
Page 1 of 3
Close Modal

or Create an Account

Close Modal
Close Modal